0001666071-23-000152.txt : 20231205 0001666071-23-000152.hdr.sgml : 20231205 20231205195313 ACCESSION NUMBER: 0001666071-23-000152 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Temsamani Karim Saad CENTRAL INDEX KEY: 0001944491 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38386 FILM NUMBER: 231468184 MAIL ADDRESS: STREET 1: C/O CARDLYTICS, INC. STREET 2: 675 PONCE DE LEON AVENUE NE, SUITE 6000 CITY: ATLANTA STATE: GA ZIP: 30308 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cardlytics, Inc. CENTRAL INDEX KEY: 0001666071 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] IRS NUMBER: 263039436 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 PONCE DE LEON AVENUE, NE STREET 2: SUITE 6000 CITY: ATLANTA STATE: GA ZIP: 30308 BUSINESS PHONE: 888-798-5802 MAIL ADDRESS: STREET 1: 675 PONCE DE LEON AVENUE, NE STREET 2: SUITE 6000 CITY: ATLANTA STATE: GA ZIP: 30308 4 1 wk-form4_1701823981.xml FORM 4 X0508 4 2023-12-01 0 0001666071 Cardlytics, Inc. CDLX 0001944491 Temsamani Karim Saad 675 PONCE DE LEON AVE. NE SUITE 6000 ATLANTA GA 30308 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-12-01 4 M 0 84079 0 A 299271 D Common Stock 2023-12-05 4 S 0 40413 8.21 D 258858 D Restricted Stock Unit 2023-12-01 4 M 0 84079 0 D Common Stock 84079 924867 D Represents the underlying vested shares of common stock of the Issuer. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on December 1, 2023. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. 25% of the RSUs vested on September 1, 2023 with the remaining 75% vesting in equal amounts over the subsequent three years quarterly thereafter, provided that the Reporting Person remains employed by the Issuer on such vesting date. /s/ NicK Lynton, Attorney-in-Fact 2023-12-05